Qualigen Therapeutics Expands Patent Portfolio Globally
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has recently made significant strides in its patent portfolio with the announcement of granted patents across 25 countries, including major markets in Europe, India, China, and Russia. This extensive coverage will further bolster the company’s commitment to advancing its cancer treatment drug, QN-302, which focuses primarily on pancreatic and gastrointestinal cancers.
Details of the New Patent Grants
The recently granted patent is titled “Substituted Naphthalene Diimides and Their Use,” and it encompasses the innovative drug developed by Professor Stephen Neidle and his research team at University College London. The patent not only covers the drug itself but also its manufacturing methods, a crucial aspect for Qualigen as it aims to produce and distribute QN-302 effectively and efficiently.
Impact on Drug Development
With these new patents in hand, Qualigen has strengthened its position in the competitive landscape of drug development, particularly within oncology. The patents are set to extend their protection until 2040, allowing the company ample time to conduct further research and bring its promising treatment to market.
CEO's Perspective
Kevin Richardson II, the CEO of Qualigen, expressed optimism regarding the company’s future following the broad patent grants. He highlighted the importance of global patent coverage for building a reliable and successful drug development pipeline. According to Richardson, securing patents that cover such a substantial part of the world’s population significantly enhances Qualigen’s capability to deliver QN-302 to patients in need, particularly those battling challenging cancers.
Global Reach of Qualigen’s Innovations
The reach of Qualigen’s new patents is noteworthy; having coverage in over 20 countries across Europe ensures that the innovative treatment can potentially benefit millions. In addition to the major European markets, the company has also established patent coverage in sizable populations in India, China, and Russia, indicating a well-rounded strategy to penetrate diverse healthcare markets.
Looking Ahead
As Qualigen continues to build its portfolio and enhance its product offerings, it plans to provide regular updates on future patent grants. The company is actively working on additional submissions and anticipates further expansions of its intellectual property rights in the near future.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is dedicated to developing innovative therapies to address significant unmet medical needs. The company focuses on advancing its drug candidate QN-302 and aims to improve treatment outcomes for patients diagnosed with cancer. For further inquiries about the company and its offerings, please reach out through their investor relations contact.
For more information about Qualigen Therapeutics, Inc., please reach out via email at ir@qlgntx.com.
Frequently Asked Questions
What is QN-302?
QN-302 is an innovative drug developed by Qualigen Therapeutics that targets pancreatic and gastrointestinal cancers.
In how many countries does Qualigen hold patents for QN-302?
Qualigen has secured patent protection for QN-302 in over 25 countries globally, covering major markets.
Who developed the drug QN-302?
QN-302 was developed by Professor Stephen Neidle and his team at University College London and is licensed by Qualigen Therapeutics.
How long will the patents for QN-302 remain in effect?
The granted patents for QN-302 will be effective until 2040, providing extensive protection for the drug's development.
What are Qualigen's future plans regarding patents?
Qualigen plans to continue pursuing additional patents and will provide updates on future grants as they occur.
